These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 2173376

  • 1. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E.
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract] [Full Text] [Related]

  • 2. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

  • 3. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T.
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F.
    Adv Neurol; 1990 Mar; 53():83-100. PubMed ID: 1978522
    [No Abstract] [Full Text] [Related]

  • 5. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T, Knott P, Kaufmann H, Yahr M.
    Adv Neurol; 1990 Mar; 53():75-81. PubMed ID: 2173378
    [No Abstract] [Full Text] [Related]

  • 6. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J.
    Adv Neurol; 1990 Mar; 53():425-9. PubMed ID: 2122648
    [No Abstract] [Full Text] [Related]

  • 7. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP, Rüther E.
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract] [Full Text] [Related]

  • 8. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E.
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract] [Full Text] [Related]

  • 9. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J.
    Wien Med Wochenschr Suppl; 1986 Jan; 98():1-18. PubMed ID: 3097965
    [Abstract] [Full Text] [Related]

  • 10. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O.
    Neurodegener Dis; 2008 Jan; 5(3-4):114-7. PubMed ID: 18322366
    [Abstract] [Full Text] [Related]

  • 11. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [Abstract] [Full Text] [Related]

  • 12. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
    Cooper JM, Daniel SE, Marsden CD, Schapira AH.
    Mov Disord; 1995 May; 10(3):295-7. PubMed ID: 7651446
    [Abstract] [Full Text] [Related]

  • 13. A review of some aspects of the pharmacology of levodopa.
    Morris JG.
    Clin Exp Neurol; 1978 May; 15():24-50. PubMed ID: 386308
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E, Hefti F.
    Adv Neurol; 1984 May; 40():149-57. PubMed ID: 6695591
    [No Abstract] [Full Text] [Related]

  • 15. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [Abstract] [Full Text] [Related]

  • 16. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 19. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U, Ljungberg T, Steg G.
    Adv Neurol; 1974 Dec; 5():421-6. PubMed ID: 4531217
    [No Abstract] [Full Text] [Related]

  • 20. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD.
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.